Surgical Director, Structural Heart Program Mount Sinai Health System

Printed as of 7/3/2024

## **Disclosures**

#### Personal Commercial (13)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Abbott Structural Heart	Other - Advisory board member, Anatomic eligibility committee member and Publications committee of the TRILUMINATE trial	Significant (>= \$5,000)	Invasive CV Angio and Interventions Valvular Heart Disease
Abbott Structural Heart	Consultant Fees/Honoraria	Significant (>= \$5,000)	Invasive CV Angio and Interventions Valvular Heart Disease
Abbott Structural Heart	Speaker's Bureau	Significant (>= \$5,000)	Invasive CV Angio and Interventions Valvular Heart Disease
Boston Scientific	Consultant Fees/Honoraria	Modest (< \$5,000)	Invasive CV Angio and Interventions Valvular Heart Disease
JenaValve	Consultant Fees/Honoraria	None (\$0)	Invasive CV Angio and Interventions Valvular Heart Disease
Medtronic	Other - Advisory board member, TAVR publications committee member, Screening committee member of the APOLLO trial and Steering committee member of the IMPACT-MR trial	Significant (>= \$5,000)	Invasive CV Angio and Interventions Noninvasive Imaging Valvular Heart Disease
Medtronic	Speaker's Bureau	Significant (>= \$5,000)	Cardiothoracic Surgery Invasive CV Angio and Interventions Valvular Heart Disease
Medtronic	Consultant Fees/Honoraria	Significant (>= \$5,000)	Valvular Heart Disease
NeoChord	Consultant Fees/Honoraria	None (\$0)	Invasive CV Angio and Interventions Valvular Heart Disease
Peija Medical	Consultant Fees/Honoraria	Modest (< \$5,000)	Invasive CV Angio and Interventions Valvular Heart Disease
Shenqi Medical Technology	Consultant Fees/Honoraria	Significant (>= \$5,000)	Invasive CV Angio and Interventions Valvular Heart Disease
Shockwave Medical	Consultant Fees/Honoraria	Modest (< \$5,000)	Invasive CV Angio and Interventions Valvular Heart Disease
Siemens Healthineers	Speaker's Bureau	Modest (< \$5,000)	Noninvasive Imaging Valvular Heart Disease

## Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (0)

No disclosures on record

## Clinical Trial Enroller (0)

No disclosures on record

#### Institutional Financial Decision-Making Role (0)

No disclosures on record

# Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

# Agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/14/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 9/14/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 6/24/2024

#### **ACC** and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.